Association Between Rs1799971 in the Mu Opioid Receptor Gene and Methadone Maintenance Treatment Response

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Oct 28

PMID 36305091

Authors

Xiaohu Xie

Jun Gu

Dingding Zhuang

Yun Zhou

Xiaoyu Chen

Wenwen Shen

Longhui Li

Yue Liu

Wenjin Xu

Qingxiao Hong

Zemin Xu

Weisheng Chen

Wenhua Zhou

Huifen Liu

Affiliations

Soon will be listed here.

Abstract

Objective: Genetic variations can affect individual response to methadone maintenance treatment (MMT) for heroin addiction. The A118G variant (rs1799971) in the mu opioid receptor gene (OPRM1) is a potential candidate single nucleotide polymorphism (SNP) for personalized MMT. This study determined whether rs1799971 is related to MMT response or dose.

Methods: We recruited 286 MMT patients from a Han Chinese population. The rs1799971 genotype was determined via TaqMan genotyping assay. The genetic effect of this SNP on MMT response or dose was evaluated using logistic regression. A meta-analysis was performed to merge all available data to evaluate the role of rs1799971 in MMT using RevMan 5.3 software.

Results: No statistical significance was observed in the association between the OPRM1 rs1799971 and MMT response or dose in our Chinese cohort. Meta-analysis indicated that the OPRM1 A118G variation was not significantly associated with MMT response or dose requirement.

Conclusion: The results suggest that rs1799971 in OPRM1 might not play a critical role alone in influencing MMT response or dose.

Citing Articles

Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessment.

Dunn K, Huhn A, Finan P, Mange A, Bergeria C, Maher B Addict Biol. 2024; 29(1):e13355.

PMID: 38221808 PMC: 10898793. DOI: 10.1111/adb.13355.

Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response.

Xie X, Gu J, Zhuang D, Zhou Y, Chen X, Shen W J Clin Lab Anal. 2022; 36(11):e24750.

PMID: 36305091 PMC: 9701885. DOI: 10.1002/jcla.24750.

References

Dennis B, Bawor M, Thabane L, Sohani Z, Samaan Z . Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014; 9(1):e86114. PMC: 3906028. DOI: 10.1371/journal.pone.0086114. View

Xie X, Liu H, Zhang J, Chen W, Zhuang D, Duan S . Association between genetic variations of NMDA receptor NR3 subfamily genes and heroin addiction in male Han Chinese. Neurosci Lett. 2016; 631:122-125. DOI: 10.1016/j.neulet.2016.08.025. View

Crews K, Monte A, Huddart R, Caudle K, Kharasch E, Gaedigk A . Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021; 110(4):888-896. PMC: 8249478. DOI: 10.1002/cpt.2149. View

Trafton J, Minkel J, Humphreys K . Determining effective methadone doses for individual opioid-dependent patients. PLoS Med. 2006; 3(3):e80. PMC: 1360079. DOI: 10.1371/journal.pmed.0030080. View

Fonseca F, Torrens M . Pharmacogenetics of Methadone Response. Mol Diagn Ther. 2017; 22(1):57-78. DOI: 10.1007/s40291-017-0311-y. View

Kreek M, Borg L, Ducat E, Ray B . Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis. 2010; 29(2):200-16. PMC: 2885886. DOI: 10.1080/10550881003684798. View

Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M . Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(7):1722-7. DOI: 10.1016/j.pnpbp.2008.07.009. View

Hartwell E, Feinn R, Morris P, Gelernter J, Krystal J, Arias A . Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020; 115(8):1426-1437. PMC: 7340566. DOI: 10.1111/add.14975. View

Mouly S, Bloch V, Peoch K, Houze P, Labat L, Ksouda K . Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015; 79(6):967-77. PMC: 4456129. DOI: 10.1111/bcp.12576. View

10.

Zhou H, Rentsch C, Cheng Z, Kember R, Nunez Y, Sherva R . Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2020; 77(10):1072-1080. PMC: 7270886. DOI: 10.1001/jamapsychiatry.2020.1206. View

11.

Haerian B, Haerian M . OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013; 14(7):813-24. DOI: 10.2217/pgs.13.57. View

12.

Xie X, Gu J, Zhuang D, Zhou Y, Chen X, Shen W . Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response. J Clin Lab Anal. 2022; 36(11):e24750. PMC: 9701885. DOI: 10.1002/jcla.24750. View

13.

Campa D, Gioia A, Tomei A, Poli P, Barale R . Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2007; 83(4):559-66. DOI: 10.1038/sj.clpt.6100385. View

14.

Fang C, Wang S, Tsou H, Chung R, Hsu Y, Liu S . Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence. J Hum Genet. 2020; 65(4):381-386. DOI: 10.1038/s10038-019-0718-x. View

15.

Wang S, Chung R, Kuo H, Liu T, Fang C, Liu S . GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence. Int J Neuropsychopharmacol. 2018; 21(10):910-917. PMC: 6165957. DOI: 10.1093/ijnp/pyy066. View

16.

Oueslati B, Moula O, Ghachem R . The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review. Pharmacogenomics. 2018; 19(8):741-747. DOI: 10.2217/pgs-2018-0017. View

17.

Crist R, Li J, Doyle G, Gilbert A, Dechairo B, Berrettini W . Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse. 2018; 44(4):431-440. PMC: 5940523. DOI: 10.1080/00952990.2017.1420795. View

18.

Hung C, Chiou M, Huang B, Hsieh Y, Hsieh T, Huang C . Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011; 12(11):1525-33. DOI: 10.2217/pgs.11.96. View

19.

Akbari A, Kheradmand A, Sina M, Ahmadiani A, Asadi S . OPRM1 and CYP3A4 association with methadone dose in Iranian patients undergoing methadone maintenance therapy. J Addict Dis. 2021; 39(3):357-362. DOI: 10.1080/10550887.2021.1886566. View

20.

Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R . β-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 2010; 11(4):258-66. DOI: 10.1038/tpj.2010.37. View